B
Bull
Bull · 25%CBIO
$15.22
Precio del escenario
$17.930
+1.436 (+8.01%)Al cierre
Loading chart…
- High
- 18.090
- Open
- 16.500
- VWAP
- 17.47
- Vol
- 788.06K
- Mkt Cap
- —
- Low
- 16.380
- Amount
- 13.76M
- EV/EBITDA, TTM
- -7.16
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
AI analysis of Crescent Biopharma, Inc. (CBIO)
buyCrescent Biopharma Inc is a good buy right now, trading at $17.75 with a 60.20% year-to-date change, indicating strong momentum. The company has a gross margin of 100% for the last two quarters, reflecting potential profitability in future operations. However, it is important to note the risk of a negative earnings per share (EPS) of -0.77 reported in the last quarter, which could impact investor sentiment.
Métricas de valoración
The current forward P/E ratio for Crescent Biopharma, Inc. (CBIO) is 0.00, compared to its 5-year average forward P/E of -1.69.
Alphio AI Price Scenarios for CBIO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CBIO
Cronología de eventos
Noticias
5.008-03GlobenewswireCrescent Biopharma Grants Stock Options to Employee
5.008-03NewsfilterCrescent Biopharma Grants Stock Options to Employee
8.507-30GlobenewswireCrescent Biopharma Advances Clinical Trials and Secures Funding
- 8.507-30Newsfilter
Crescent Biopharma Advances Clinical Trials and Secures Funding
8.507-15NASDAQ.COMCrescent Biopharma Prices Public Offering at $14.50 per Share
CBIO FAQ — answered by Alphio AI
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications. It operates in the Healthcare sector.
Crescent Biopharma Inc is a good buy right now, trading at $17.75 with a 60.20% year-to-date change, indicating strong momentum. The company has a gross margin of 100% for the last two quarters, reflecting potential profitability in future operations. However, it is important to note the risk of a negative earnings per share (EPS) of -0.77 reported in the last quarter, which could impact investor sentiment.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.